Revenue YoY
—
Operating Income YoY
-75.68%
Net Income YoY
-96.70%
Net Margin Δ
—
Net income bridge for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: -$674M-96.70%
Profit bridge breakdown for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | -$698M | — |
| Revenue | $0.00 | +0.0% |
| Cost of Revenue | -$9.24M | -1.4% |
| Operating Expenses | -$588M | -87.2% |
| Other Income / Expense | -$76M | -11.3% |
| Income Tax | -$753K | -0.1% |
| Net Loss | -$1.37B | — |
- Prior Net Income-$698M
- Revenue$0.00
- Cost of Revenue-$9.24M
- Operating Expenses-$588M
- Other Income / Expense-$76M
- Income Tax-$753K
- Net Loss-$1.37B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.